Last reviewed · How we verify
Transdermal strogen
Transdermal estrogen delivers estradiol through the skin to replace or supplement endogenous estrogen levels.
Transdermal estrogen delivers estradiol through the skin to replace or supplement endogenous estrogen levels. Used for Menopausal vasomotor symptoms (hot flashes, night sweats), Moderate to severe menopausal vulvar and vaginal atrophy, Hypoestrogenism and estrogen deficiency states.
At a glance
| Generic name | Transdermal strogen |
|---|---|
| Sponsor | Parc de Salut Mar |
| Drug class | Hormone replacement therapy (HRT) / Estrogen replacement |
| Target | Estrogen receptor alpha (ERα) and estrogen receptor beta (ERβ) |
| Modality | Small molecule |
| Therapeutic area | Endocrinology / Women's Health |
| Phase | FDA-approved |
Mechanism of action
The patch formulation allows continuous, steady-state delivery of estradiol across the skin barrier into systemic circulation, bypassing first-pass hepatic metabolism. This provides more stable hormone levels compared to oral formulations and reduces fluctuations in estrogen exposure. The estrogen acts on estrogen receptors throughout the body to address symptoms and conditions related to estrogen deficiency.
Approved indications
- Menopausal vasomotor symptoms (hot flashes, night sweats)
- Moderate to severe menopausal vulvar and vaginal atrophy
- Hypoestrogenism and estrogen deficiency states
Common side effects
- Breast tenderness
- Headache
- Nausea
- Skin irritation at patch site
- Vaginal bleeding or spotting
- Fluid retention
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Transdermal strogen CI brief — competitive landscape report
- Transdermal strogen updates RSS · CI watch RSS
- Parc de Salut Mar portfolio CI